Trials / Active Not Recruiting
Active Not RecruitingNCT06073574
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
The CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
Detailed description
This pilot study will determine the efficacy of ION-682284 in reducing the amyloid deposit on the heart tissue compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Cardiac MRI | MRI Scans as specified in the corresponding arm group. |
Timeline
- Start date
- 2021-03-31
- Primary completion
- 2026-03-01
- Completion
- 2026-04-01
- First posted
- 2023-10-10
- Last updated
- 2025-11-28
Locations
11 sites across 4 countries: United States, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT06073574. Inclusion in this directory is not an endorsement.